Robert M. Califf, MD, was sworn in as the new commissioner of the U.S. Food and Drug Administration (FDA) on February 17, 2022.
Previously, Dr. Califf served as FDA commissioner from February 2016–February 2017. Prior to rejoining the FDA, Dr. Califf was head of medical strategy and senior advisor at Alphabet Inc., contributing to strategy and policy for its health subsidiaries, Verily Life Sciences and Google Health. He also served as director of the Duke Translational Medicine Institute and founding director of the Duke Clinical Research Institute.
A nationally and internationally recognized expert in cardiovascular medicine, health outcomes research, health-care quality, and clinical research, Dr. Califf has led many landmark clinical trials and is one of the most frequently cited authors in biomedical science, with more than 1,300 publications in the peer-reviewed literature.
Dr. Califf will now oversee the federal agency tasked with finalizing and implementing over-the-counter hearing aid regulations.
Recent Posts
Senate Passes Continuing Resolution: What It Means for Hearing Health
The Senate recently passed a continuing resolution (CR) to keep the federal government funded through December 11, 2026, giving Congress additional time to complete the…
General Audiology Board Certification (GABC): Historical, Current and Future Perspectives and Why It Matters
Like many other healthcare professionals, audiologists have the dubious distinction of the “alphabet signature” indicating our training and education, our expertise, and commitment to our…



